SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently driving intense conversation after its recent earnings report significantly beat expectations and delivered robust guidance, sparking strong bullish sentiment around its AI growth while also reigniting debates over its high valuation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after announcing strategic acquisitions that more than double its total infrastructure capacity to 2.8 GW, significantly expanding its footprint for high-performance computing and AI data centers. The community views this as a "transformational" move, anticipating a potential short squeeze and a re-rating of the stock as it solidifies its position as a key AI infrastructure player.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as hyperscalers like Microsoft and Meta signal unprecedented demand for AI infrastructure, with investors looking to upcoming earnings for further catalysts amidst community debate over recent stock volatility and long-term potential.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne (TER) is trending after reporting strong Q4 earnings and issuing Q1 guidance significantly above analyst expectations, driven by robust AI-related demand in compute and chip testing. The community is actively discussing the impressive beat and notable after-hours price surge, with many anticipating continued momentum from the expanding AI sector.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to considerable outflows from its Bitcoin ETF, fueling community discussions over whether the current crypto downturn signals a deepening "crypto winter" or an opportune moment to buy the dip.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoin is experiencing high volatility as institutional ETFs see significant inflows despite recent price dips, sparking community debate on whether the asset has found a bottom. Market participants are closely watching regulatory developments and geopolitical shifts for clues on its 'digital gold' narrative and next directional move.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney's stock is trending lower despite reporting strong earnings and an announced $7 billion share buyback, as the community actively debates the post-earnings sell-off and anticipates clarity on CEO succession amidst its multi-year underperformance.

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

Perspective Therapeutics Inc

Perspective Therapeutics (CATX) is trending with high volume after an announced $175 million equity offering, polarizing the community between those who see it as a strategic move attracting institutional interest and extending cash runway, and others concerned about dilution. This comes amidst speculation around a potential buyout and reduced competition in the radiopharmaceutical sector, following Sanofi's deprioritization of a competing therapy.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending amid community buzz following the recent FDA approval of an updated Afrezza label for clearer dosing guidance, with widespread debate on whether this and the Afrezza launch in India will overcome historical challenges and high short interest to drive significant sales, alongside ongoing pipeline catalysts.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as its stock experiences a significant sell-off despite reporting a strong quarter with accelerating growth and customer acquisition, leading to widespread community frustration and claims of market manipulation. Investors are actively debating whether this is a "buy the dip" opportunity given historically oversold conditions and potential S&P 500 inclusion in March, or if recent equity offerings and analyst downgrades signal further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Exagen Inc. (NASDAQ:XGN) Expands By 65.7%

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,793,289...

Exagen's (XGN) "Buy" Rating Reaffirmed at B. Riley

B. Riley restated a "buy" rating and issued a $8.00 price objective (down previously from $18.00) on shares of Exagen in a research note on Friday...

Exagen Inc. (NASDAQ:XGN) Sees Large Growth in Short Interest

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,082,304...

Exagen Inc. (NASDAQ:XGN) Given Consensus Rating of "Moderate Buy" by Brokerages

Exagen Inc. (NASDAQ:XGN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the firm, Marketbeat reports. One investment...

67,600 Shares in Exagen Inc. $XGN Bought by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI purchased a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The...

75,413 Shares in Exagen Inc. $XGN Acquired by Calamos Advisors LLC

Calamos Advisors LLC acquired a new stake in shares of Exagen Inc. (NASDAQ:XGN - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities...

BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock

BTIG Research increased their price objective on Exagen from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Monday...

Cantor Fitzgerald Forecasts Weaker Earnings for Exagen

Exagen Inc. (NASDAQ:XGN - Free Report) - Cantor Fitzgerald decreased their FY2026 earnings per share estimates for shares of Exagen in a research note issued to investors on Wednesday, November 5th...

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of -46.15% and +0.55%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of 0.00% and +7.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Exagen Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMD earnings on Tuesday?

Current Price	$3.83
Prev Close	$3.68
Open	$3.64
Dividend Yield	0.00%
50-Day Moving Average	$6.16
Beta	1.07
Avg. Volume	681,246.55
PE Ratio	-4.14

52-Week High	$12.23
52-Week Low	$2.67
Market Capitalization	$83.4M
EPS (Annual)	-$0.8304
Price to Book	4.75
Revenue Per Employee	$266,224.88
Enterprise Value/EBITDA	N/A

XGN
Exagen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XGN News

XGNExagen Inc